#Sweden #AGM #Stockholm #Sobi

Swedish Orphan Biovitrum AB (Sobi) Annual General Meeting 2026

On March 27, 2026, Swedish Orphan Biovitrum AB (publ), commonly known as Sobi®, announced its invitation to shareholders for its Annual General Meeting (AGM) scheduled for May 6, 2026. The meeting will be held at IVA Konferenscenter, located at Grev Turegatan 16, Stockholm, Sweden. Shareholders will have the opportunity to engage in key discussions and make crucial decisions regarding the company's governance and operations.

Meeting Participation Details

Participation in the AGM is open to individuals listed as shareholders as of April 27, 2026, according to the share register maintained by Euroclear Sweden AB. Shareholders intending to attend must register their participation by April 29, 2026. This can be done via the Euroclear website, by mail, or through e-mail. It is important to provide full identification details, including name, address, contact number, and in cases where proxies are involved, necessary authorization documents must be submitted as well.

For those unable to attend in person, Sobi also provides the option for postal voting. However, shareholders opting for this method must ensure that their votes reach Euroclear by April 29, 2026.

Agenda and Key Topics

The AGM will kick off with the election of the meeting chair and the approval of the voting list, followed by the presentation of essential financial documents such as the annual report and auditor's report. Company leadership will present the results of their operations over the past year and share insights on future strategies.

Election of Board Members

One of the critical points of the meeting will be the re-election and election of Board members. The Nomination Committee has proposed several members, including Christophe Bourdon, Iris Loew-Friedrich, David Meek, and others, to ensure the company remains driven by experienced leaders. There will also be discussions regarding the appointment of Ernst & Young AB as the company's auditor.

Financial Allowances and Remuneration

Additionally, discussions will cover the remuneration report, where the committee will present proposed fees for Board members. The suggestion indicates an increase in fees for certain committees, reflecting the growing responsibilities entrusted to the Board.

Furthermore, resolutions will be made concerning the implementation of long-term incentive programs aimed at benefiting Sobi’s employees. These programs, designed to foster a sense of ownership and align employees' interests with those of shareholders, will be an integral part of Sobi's strategy moving forward. The Board believes such initiatives will significantly bolster employee engagement and retention during critical growth phases.

Conclusion

With a significant shareholding structure, Sobi continues to pave its way in the biopharma landscape. The AGM is expected to draw a notable number of shareholders who will contribute to the dialogue regarding the company's future direction and governance. For more information regarding the AGM and the voting process, shareholders are encouraged to visit Sobi's official website.

In conclusion, Sobi’s upcoming AGM promises to be a crucial platform for decision-making and a chance to reflect on the company's achievements and aspirations moving forward. Stakeholders are looking forward to active participation and robust discussions to ensure Sobi continues to thrive in the competitive biopharmaceutical industry.